Novo Nordisk A/S (NVO) Projected to Announce Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.7310 per share and revenue of $11.08 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion for the quarter. On average, analysts expect Novo Nordisk A/S to post $3.42 EPS for the current fiscal year and $3.42 EPS for the next fiscal year.

Novo Nordisk A/S Stock Down 0.1%

NVO opened at $39.96 on Monday. The company has a market capitalization of $178.42 billion, a PE ratio of 9.77, a price-to-earnings-growth ratio of 1.36 and a beta of 0.70. The firm has a 50-day simple moving average of $41.23 and a two-hundred day simple moving average of $44.34. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a $0.5786 dividend. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a dividend yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a report on Tuesday, September 29th. Barclays reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. Finally, Berenberg Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $59.44.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s new 2030 targets emphasize pipeline expansion, broader treatment offerings and the goal of serving more patients. The strategy could help reduce the company’s dependence on its current GLP-1 franchise and support a long-term recovery. Novo Nordisk Sets New 2030 Goals As GLP-1 Competition Builds
• Positive Sentiment: The global weight-loss market is forecast to expand substantially through 2036, providing a large long-term opportunity for Novo Nordisk as demand grows for GLP-1 drugs, oral therapies, telehealth and direct-to-patient distribution. Global Weight Loss Market Size, Share, Trends and Forecast
• Positive Sentiment: Erste Group Bank maintained a bullish outlook for Novo Nordisk’s fiscal 2026 earnings, while recent commentary argues that the shares’ sharp multi-year decline has left the company looking inexpensive relative to its earnings potential. Erste Group Bank Has Bullish Outlook for NVO FY2026 Earnings
• Neutral Sentiment: Novo Nordisk is receiving elevated investor attention, but trending-stock coverage primarily highlights factors to monitor rather than a new fundamental catalyst. What to Know Beyond Why Novo Nordisk Is a Trending Stock
• Negative Sentiment: Eli Lilly’s strong results and raised outlook reinforce its lead in obesity drugs, underscoring the competitive pressure facing Novo Nordisk. Investors may require stronger pipeline execution and evidence that the 2030 plan can offset slowing momentum in current GLP-1 products. Eli Lilly Jumps as Strong Quarter Lifts Revenue Outlook

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.